In Bangkok in 2004, Nelson Mandela said 'To fight against AIDS, we must do more to fight TB'. To date, this advice has gone largely unheeded. However, in high HIV and TB prevalent areas, typified by most countries in sub-Saharan Africa, HIV-related mortality will not be reduced unless due attention is paid to TB, and TB burden and TB cure rates will not improve unless due attention is paid to HIV/AIDS. This issue of Tropical Doctor has five papers addressing the complex problem of 'HIV and TB'. Each should be regarded as a stand-alone paper, although together they provide an up-to-date review of the interaction between HIV and TB and the key interventions that, if implemented, may help to reduce the dual burden of HIV and TB.
Babajide Keshinro and Mukadi Ya Diul review the epidemiology, clinical manifestations and diagnosis of smear-negative pulmonary TB (PTB). About one-third of the world's population is infected with Mycobacterium tuberculosis, although the lifetime risk of developing active TB in such people is only 10%. Many factors increase that overall risk, including age of infection, immunosuppressive drugs and concomitant disease such as diabetes mellitus and silicosis. However, all pale into insignificance when compared with HIV. This virus, by targeting CD4-T-lymphocytes and reducing cellular immune function, is the strongest driving force behind the current TB epidemic. In those co-infected with HIV and M. tuberculosis, the annual risk of active TB is 5-15%, and the risk increases as the immune system becomes more and more compromised. 1 In 2000, there were 24 million people estimated to be co-infected with the virus and bacterium, with the large majority living in sub-Saharan Africa. 2 Currently across this region, onethird of TB cases are HIV-seropositive, although in several African countries these rates are much higher. For example, in South Africa, Namibia, Botswana, Zambia and Malawi, these rates are all between 60% and 80%. 3 Despite good 'DOTS' (directly observed treatment, short-course) TB control programmes in many countries in sub-Saharan Africa, the strong association between HIV and M. tuberculosis has had, and continues to have, a deleterious effect on TB control efforts. Case notification rates have escalated, in some countries increasing by a factor of 500% in the last 15-20 years. Large case numbers have thrown an immense strain on TB control programmes, necessitating more staff, more drugs, more stationary, more laboratory resources and more funds. Although extra-pulmonary TB (EPTB) accounts for up to 25% of all cases, the most common clinical manifestation of HIV-associated TB is still pulmonary disease. However, the clinical pattern of PTB becomes more atypical as the immune system becomes more compromised, and infiltrative, lower lobe, smear-negative disease tends to dominate the clinical picture in severely immunosuppressed individuals. The accurate diagnosis of smearnegative PTB poses a huge challenge in the resource-poor arena that typifies most African hospitals. 4 Joseph Odjiambo and Kevin de Cock discuss the issue of HIV testing in TB patients. Sub-Saharan Africa bears the brunt of the HIV epidemic, and is the home to nearly 26 million adults and children living with HIV infection. 5 However, throughout that continent, the majority of HIV-infected people do not know their HIV status. This has to change. Given the strong association between HIV and TB, HIV testing for TB patients, using rapid tests, is the entry point to a continuum of prevention, care, support and treatment for HIV/AIDS as well as for TB. The World Health Organization (WHO) recommends that HIV testing and counselling be offered to all TB patients in settings where the HIV prevalence among TB patients is 5% or higher. 6 WHO further recommends that TB control programmes mainstream provision of HIV testing and counselling in their operations or establish a referral linkage with HIV/AIDS programmes to do so. Provider-initiated HIV testing should become a part of the standard package of care of TB patients in areas of high HIV prevalence.
Knowing the HIV status of a TB patient allows the use of two potentially effective interventions. The first is the adjunctive use of cotrimoxazole preventive therapy to reduce morbidity and mortality, a topic covered by Rony Zachariah and Moses Massaquoi. Cotrimoxazole has been used for many years in industrialized countries, mainly to prevent a first or recurrent episode of Pneumocystis jiroveci pneumonia. It was hardly considered in Africa until a seminal study was conducted in Cote d'Ivoire, showing that cotrimoxazole in HIV-positive TB patients reduced mortality by 40% and hospital admissions by nearly 50%. 7 The results of this study, published in 1999 in the Lancet, persuaded WHO and UNAIDS to issue provisional recommendations about the widespread use of cotrimoxazole in HIV-positive adults and children in Africa. 8 Ongoing randomized controlled trials assessing the efficacy of cotrimoxazole in South Africa and Malawi, where the pattern of HIV and antibiotic resistance profiles differed markedly from West Africa, were prematurely and unwisely terminated. For the next 5 years, most countries in East, Central and Southern Africa failed to implement the provisional recommendations because of concerns about efficacy and about what the widespread use of cotrimoxazole might do to antimalarial treatment. However, health-care workers did not stand idle during this time. Operational research studies in Malawi using historical controls, 9, 10 observational studies in Uganda 11 and a new randomized placebo-controlled trial in Zambia 12 eventually provided the evidence base that cotrimoxazole in this part of Africa is 'good' for HIVpositive patients. Furthermore, the risk of compromising antimalarial treatment may not be as worrisome as was previously believed. 13 The next challenge is scaling up and sustaining this intervention, not only for TB patients, but also for all those HIV-positive individuals who are eligible for treatment.
The second potentially effective intervention is highly active antiretroviral therapy (HAART), a subject covered by Soumya Swaminathan, Annie Luetkemeyer, Padmini Srikantiah, Royce Lin, Edwin Charlebois and Diane Havlir. Many high HIV-prevalent African countries are Tropical Doctor April 2006, 36 scaling up HAART, in line with WHO's '3 by 5' initiative, i.e., to place three million people in developing countries on HAART by the end of 2005. Progress is being made. For example, by June 2005, 500,000 patients in Africa had been started on HAART, a threefold increase in numbers compared with 12 months previously. 14 HAART may be highly beneficial for these patients in reducing HIV-related case fatality rates and the risk of recurrent TB. However, concomitant ART during anti-TB treatment is not easy, and is complicated specifically by high pill burden, additive drug toxicities, drug-drug interactions and the paradoxical immune reconstitution disease. 15 The optimum time to start HAART is not known. Much of the mortality in HIVpositive TB patients occurs during the first 2 months of anti-TB treatment, and thus starting HAART at this time might seem advantageous. However, patients in the early phases of treatment are sick, and the early introduction of HAART might pose a significant threat in terms of additive drug toxicity and immune reconstitution disease. There is also an inherent tension between the way HAART is delivered (currently through hospital-based clinics) and the way anti-TB treatment is delivered (through health centres as a result of decentralized management over the last 5-10 years). 16 Expecting TB patients on a monthly basis to collect their anti-TB drugs from health centres, and then come from remote parts of the district to collect antiretroviral drugs from a hospital is unrealistic. Solutions to all these problems need to be found if HIV-positive TB patients are to reap the full benefits of HAART.
HIV-positive individuals are at high risk of TB. Even for HIV-infected persons on HAART, the risk of TB is higher than individuals who are HIV negative. Thus, the last article in this series from Helen Ayles and Monde Muyoyeta on isoniazid preventive therapy is important. The efficacy of isoniazid preventive therapy in reducing the incidence of TB in HIV-positive individuals has been well demonstrated through several randomized controlled trials, where the effect is particularly marked in those who have a positive tuberculin skin test. 17 Isoniazid is as effective as, and safer than, rifampicin-and pyrazinamidecontaining regimens, and is the preferred drug for this intervention. However, isoniazid preventive therapy requires several steps to be taken, including identification of HIV-positive subjects, and screening to exclude active TB and drug adherence. For these reasons, the feasibility of this intervention in resource-poor countries is difficult, particularly as there are no established structures to monitor the process or the outcome.
HIV-positive patients who have completed a course of anti-TB treatment are at an increased risk of recurrent TB, particularly where the continuation phase contains a non-rifampicin-containing combination. 18, 19 Studies in Haiti and South Africa have found that post-treatment isoniazid significantly reduces the rate of recurrent TB. 20, 21 However, this intervention has yet to find a place in the routine management of TB. If the main mechanism of recurrence is re-infection, which appears to be the case in HIV-infected individuals who develop recurrent TB several months after completing treatment, then isoniazid may need to be given for life. As yet, the structures for delivering and monitoring such an intervention do not exist, and whether isoniazid needs to be given if patients are also on HAART is not known.
Scaling up and sustaining the key HIV-related interventions discussed in this theme issue would go a long way in reducing the burden of TB and case fatality rates associated with anti-TB treatment. The millennium development goals specifically mention targets around TB, namely to reduce the prevalence and mortality of TB by 50% by the year 2015. 22 It is unlikely that these targets will be reached in sub-Saharan Africa without institutionalizing HIV testing and counselling for TB patients, providing cotrimoxazole and HAART for HIV-positive TB patients and preventing the development of active TB in HIV-infected persons through isoniazid preventive therapy. The funds, as never before, are there to allow scaling up and implementation. What are required now are will, leadership and determination at all levels of the health sector to see the rhetoric translate into action on the ground. Patients with TB and HIV/AIDS deserve no less. 
Anthony D Harries MD FRCP

